Tumeur du foie non opérable (HCC) ou non-HCC
Talimogene Laherparepvec (T-VEC), Pembrolizumab
BC, GEC, melanoma, NSCLC, RCC with liver metastatis or HCC (PD)
Subjects must not be candidates for hepatic surgery or locoregional therapy of liver tumors
Liver tumors must not be estimated to invade approximately more than one-third of the liver
HCC: monotherapy /TVEC+Pembrolizumab
The study consists of 2 parts and 2 groups, and Part 2 includes 2 stages. The objective of Part 1 is to evaluate the safety of intrahepatic injection of talimogene laherparepvec into liver tumors alone and in combination with systemically administered pembrolizumab for the non-HCC (Group A) and HCC (Group B) cohorts separately. Part 2 consists of 2-stage design to evaluate the efficacy and safety of talimogene laherparepvec in combination with systemic pembrolizumab. Efficacy and safety will be evaluated in each of the six non-HCC tumor types from Group A separately. Similarly, the efficacy and safety of the combination treatment will be determined for Group B HCC subjects.